Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event ofany discrepancy between this translation and the Japanese original, the original shall prevail.

Securities code: 2309
November 30, 2021
To our shareholders,Kazuo Nakamura
Chairman & CEO
CMIC HOLDINGS Co., Ltd.
1-1-1 Shibaura, Minato-ku, Tokyo

Notice of the Convocation of the 37th Ordinary General Meeting of
Shareholders
We are pleased to announce the 37th Ordinary General Meeting of Shareholders of CMIC HOLDINGS Co.,
Ltd. (the “Company”), which will be held as described below.
To mitigate the risk of infection of the novel coronavirus disease (COVID-19), you are strongly urged torefrain from traveling to the venue on the date of the meeting regardless of your own state of health.
Shareholders who are elderly, have any underlying disease, or are pregnant are strongly requested to exercise
careful judgment, as people in such conditions are perceived to be significantly affected by the infection.
Instead of attending the meeting in person, you may exercise your voting rights in writing or via the internet,
etc. Please review the attached “Reference Documents for the General Meeting of Shareholders” below to
exercise your voting rights.
1. Date and time:
2. Place:

Wednesday, December 15, 2021 at 10:00 a.m.
Main Hall, Hamamatsucho Convention Hall (Nippon Life Hamamatsucho Crea
Tower 5F)
2-3-1 Hamamatsucho, Minato-ku, Tokyo

3. Agenda:
Matters to be reported:
1. Report on the business report, the consolidated financial statements for the 37th fiscal year (fromOctober 1, 2020 to September 30, 2021) and the results of the audit of the consolidated financial
statements by the financial auditor and the Audit and Supervisory Board
2. Report on the non-consolidated financial statements for the 37th fiscal year (from October 1, 2020
to September 30, 2021)
Matters to be resolved:
Proposal 1: Amendment to the Articles of Incorporation
Proposal 2: Election of Eleven (11) Corporate Directors
4. Exercise of voting rights by proxy:
If you exercise your voting rights by proxy, you may designate one other shareholder holding voting
rights in the Company to attend the meeting. Please note, however, that it is necessary to submit adocument proving the authority of the proxy.
Any modifications to the Reference Documents for the General Meeting of Shareholders will be posted on
the Company’s website (https://www.cmicgroup.com; in Japanese only).

1Reference Documents for the General Meeting of Shareholders
Proposal 1:

Amendment to the Articles of Incorporation

1. Reason for the proposal
In order to prepare for the future business development and diversification of business activities of theCompany and the Group, we propose that a business purpose be added to Article 2 (Purpose) of thecurrent Articles of Incorporation, and that the item numbers be moved down in accordance with theestablishment of the new items.
2. Details of the Changes
The changes are as follows:(Underlined parts are the changes)
Proposed Amendments

Current Articles of Incorporation

Article 2 (Purpose)
Article 2 (Purpose)
1. The Company is organized for the purpose of engaging(Unchanged)
in the following businesses and controlling andmanaging the business activities of the companies(including foreign companies), associations (including
those equivalent to associations in any foreign country),and other business entities similar thereto that engage inthe following businesses by owning the shares or equityof such companies, etc.
(1) – (23)(Text omitted)(1) – (23)(Unchanged)(Newly established)(24) Works related to the management and operation of
hotels, training centers, and other lodging facilities
and auxiliary facilities(Newly established)(25) Works related to the cultivation, processing and saleof agricultural products(Newly established)(26) Warehousing business(24) – (25)(Text omitted)(27) – (28)(Unchanged)
2. The Company aims to engage in any and all businesses
2.
(Unchanged)
ancillary or related to the preceding paragraph.

2

Proposal 2:

Election of Eleven (11) Corporate Directors

At the conclusion of this Ordinary General Meeting of Shareholders, the terms of office of all eleven (11)Corporate Directors will expire. In that regard, in order to further enhance the corporate governance andaccelerate the globalization, the Company proposes to elect a total of eleven (11) Corporate Directors (ofwhich, four (4) are to be External Corporate Directors), including two (2) new candidates (of which, one (1)is to be an External Corporate Director).
The candidates for Corporate Director are as follows:
Candidate
No.

Name

Position in the Company

Candidate attributes

1

Kazuo Nakamura

Representative Director,
Chairman and CEO

Reelection

2

Keiko Oishi

Representative Director,
President and COO

Reelection

3

Makoto Matsukawa

Corporate Director and CVO

Reelection

4

Wataru Mochizuki

Corporate Director and CFO

Reelection

5

Toru Fujieda

Corporate Director

Reelection

6

Takeshi Hamaura

Corporate Director

Reelection

7

Yoshiyuki Inamoto

Vice President

New election

8

Masaru Iwasaki

External Corporate Director

Reelection

External

9

Takeshi Karasawa

External Corporate Director

Reelection

External

Independent

10

Eriko Kawai

External Corporate Director

Reelection

External

Independent

11

Gregg Lindstrom Mayer–

New election

External

Independent

Note:

Ms. Keiko Oishi’s name on the family register is Keiko Nakamura.

3

Candidate No.

1

Reelection
Number of the Company’s shares owned: 564,220 shares
Attendance to meetings of the Board of Directors: 12/12 (100%)[Career summary, and position and responsibility in the Company]
Apr. 1969 Joined Sankyo Co., Ltd. (currently Daiichi Sankyo Co., Ltd.)Mar. 1992 Representative Director and President, the Company

Kazuo Nakamura(December 17, 1946)

Oct. 2003

Representative Director, Chairman and President CEO, the Company

Dec. 2013

Representative Director, Chairman and President CEO, the Company (change
of Japanese title only)

Apr. 2018

Representative Director, Chairman and CEO, the Company

Apr. 2021

Representative Director, Chairman and CEO, the Company (to present)(change of Japanese title only)

Oct. 2021

Division Director of Healthcare Revolution Business, the Company (topresent)

Significant concurrent positions outside the Company:
Representative Director, Chairperson, harmo Co., Ltd.
[Reasons for nomination as candidate for Corporate Director]
After working in research and development at a large pharmaceutical corporation, Mr.
Kazuo Nakamura founded the Company. He possesses outstanding abilities in executive
management, which he has used to steer the Company as a leading company. As theCompany expects him to continue to perform a decision-making and supervisory role inmanagement, it again nominated him as a candidate for Corporate Director.

4Candidate No.

2

Reelection
Number of the Company’s shares owned: 152,900 shares
Attendance to meetings of the Board of Directors: 12/12 (100%)[Career summary, and position and responsibility in the Company]
Apr. 1982 Joined Nikkei/McGraw-Hill Inc. (currently Nikkei Business Publications, Inc.)

Keiko Oishi(January 3, 1957)

Oct. 1989

Joined Genentech, Inc.

Jan. 1996

Joined the Company

July 2000

Corporate Director, the Company

Oct. 2004

Corporate Director and Vice President, the Company

Dec. 2010

Representative Director, the Company

Apr. 2011

Representative Director, Corporate Officer, in charge of International Business,
the Company

Dec. 2013

Representative Director, Executive Vice President, Division Head ofInternational Business Development Div., the Company

Oct. 2016

Representative Director, Executive Vice President, CEO of CRO Business,
Division Head of International Business Management Div., the Company

Apr. 2018

Representative Director, President and COO, Supervisory Manager of Business
Development & Marketing, the Company

Apr. 2021

Representative Director, President and COO, CHO, Supervisory Manager ofBusiness Development & Marketing, the Company(Name on the family register:Oct. 2021
Keiko Nakamura)

Representative Director, President and COO, Division Director of CRO
Business, the Company (to present)

Significant concurrent positions outside the Company:
Representative Director, Chairperson, CMIC Co., Ltd.
Representative Director, Chairperson, CMIC HealthCare Institute Co., Ltd.
Representative Director and Vice President, CMIC ShiftZero K.K.
[Reasons for nomination as candidate for Corporate Director]
With extensive experience at international corporations, Ms. Keiko Oishi has been amember of the Company’s senior management since the Company was founded, and she
possesses outstanding abilities in executive management. During her time as President of
the Company, her efforts toward “globalization” and “training of personnel for
globalization” particularly stand out. As the Company expects her to continue to perform adecision-making and supervisory role in management, it again nominated her as a candidate
for Corporate Director.

5Candidate No.

3

Reelection
Number of the Company’s shares owned: 2,480 shares
Attendance to meetings of the Board of Directors: 12/12 (100%)[Career summary, and position and responsibility in the Company]
Apr. 1984 Joined Akiyama Inc. (currently SUZUKEN CO., LTD.)

Makoto Matsukawa(March 30, 1960)

Oct. 1989

Joined Baxter Limited

June 1999

Joined Starbucks Coffee Japan, Ltd.

Apr. 2007

Joined Quintiles Transnational Japan K.K. (currently IQVIA Services Japan
K.K.)

Jan. 2012

Joined the Company, Corporate Officer, in charge of Corporate Planning/IPD

Dec. 2012

Corporate Director, Corporate Officer and IPD Company President, theCompany

May 2015

Senior Executive Officer, in charge of Business Development, the Company

Oct. 2016

Senior Executive Officer, in charge of Business Development, CEO of CDMO
Business, the Company

Dec. 2016

Corporate Director, the Company

Apr. 2018

Corporate Director and Executive Vice President, Supervisory Manager of
CDMO, Supervisory Manager of CSO, the Company

Nov. 2018 Corporate Director and Executive Vice President, Supervisory Manager of
CDMO, the Company
Apr. 2021

Corporate Director and CVO, Division Director of CDMO Business, theCompany (to present)

Significant concurrent positions outside the Company:
Representative Director & CEO, CMIC CMO Co., Ltd.
[Reasons for nomination as candidate for Corporate Director]
Having started up businesses in various industry sectors including not only thepharmaceutical sector, but also large-player service sector, Mr. Makoto Matsukawa
possesses management experience and plays an instrumental role in globalization andstrategic business development within the Company. As the Company expects him tocontinue to perform a decision-making and supervisory role in management, it again
nominated him as a candidate for Corporate Director.

6

Candidate No.

4

Reelection
Number of the Company’s shares owned: 4,380 shares
Attendance to meetings of the Board of Directors: 12/12 (100%)[Career summary, and position and responsibility in the Company]
Apr. 1985 Joined Nippon Oil & Fats Co., Ltd. (currently NOF CORPORATION)
Jan. 1997

Joined Allied Telesis Holdings K.K.

Aug. 2005 Joined the Company
Oct. 2010
Dec. 2010

Corporate Director, the Company

Oct. 2012

Corporate Director, Corporate Officer and CFO, in charge of Internal
Control/Information Disclosure, the Company

Oct. 2013

Corporate Director, Senior Corporate Officer and CFO, in charge of Financeand Legal Affairs Department/Internal Control/Information Disclosure, theCompany

May 2015

Corporate Director, Executive Vice President and CFO, in charge of Internal
Control/Information Disclosure, the Company

Apr. 2018

Corporate Director, Executive Vice President and CFO, Supervisory Manager
of Administration and Support Unit, the Company

Apr. 2021

Corporate Director and CFO, responsible for Group Information
Disclosure/Internal Control, the Company (to present)

Wataru Mochizuki(December 10, 1961)

Corporate Officer, in charge of Internal Control/Information
Disclosure/Finance and Accounting, the Company[Reasons for nomination as candidate for Corporate Director]
With extensive knowledge and experience in administrative departments, Mr. Wataru
Mochizuki possesses outstanding abilities in executive management. As the Company
expects him to continue to perform a decision-making and supervisory role in management,
it again nominated him as a candidate for Corporate Director.

7

Candidate No.

5

Reelection
Number of the Company’s shares owned: 4,880 shares
Attendance to meetings of the Board of Directors: 12/12 (100%)[Career summary, and position and responsibility in the Company]
Apr. 1984 Joined Sankyo Co., Ltd. (currently Daiichi Sankyo Co., Ltd.)
June 2004

General Manager of Clinical Development Department, Sankyo Co., Ltd.

Feb. 2016

Joined the Company, Senior Corporate Officer

Oct. 2016

President, CMIC Co., Ltd. (to present)

Corporate Director and Executive Vice President, CMIC Co., Ltd.

Toru Fujieda(November 8, 1959)

Dec. 2016

Corporate Director and Executive Vice President, the Company

Apr. 2018

Corporate Director and Executive Vice President, Supervisory Manager ofClinical CRO, the Company

Apr. 2021

Corporate Director, Supervisory Manager of Clinical CRO, the Company

Oct. 2021

Corporate Director, Deputy Division Director of CRO Business (in charge ofClinical CRO Business), the Company (to present)

Significant concurrent positions outside the Company:
President, CMIC Co., Ltd.
[Reasons for nomination as candidate for Corporate Director]
With extensive experience in clinical development and management experience at a large
pharmaceutical corporation, Mr. Toru Fujieda plays an instrumental role in the CRO
business for the Company. As the Company expects him to continue to perform a decisionmaking and supervisory role in management, it again nominated him as a candidate for
Corporate Director.

8

Candidate No.

6

Reelection
Number of the Company’s shares owned: 1,680 shares
Attendance to meetings of the Board of Directors: 12/12 (100%)[Career summary, and position and responsibility in the Company]
Apr. 1985 Joined Sankyo Co., Ltd. (currently Daiichi Sankyo Co., Ltd.)
Apr. 2012

Vice President of Supply Chain Technology Department, Daiichi Sankyo Co.,Ltd.

Apr. 2014

Vice President of CMC Planning Department, Daiichi Sankyo Co., Ltd.

Apr. 2017

Head of Pharmaceutical Technology Division, Daiichi Sankyo Co., Ltd.

Oct. 2019

Joined the Company, General Manager in charge of CDMO Business
Promotion, Strategy Management Div.

Nov. 2019 Executive Vice President and CTO, Assistant to Supervisory Manager of
CDMO, the Company

Takeshi Hamaura

Dec. 2019

Corporate Director, the Company(November 15, 1960)

Apr. 2021

Corporate Director, Deputy Division Director of CDMO Business (to present)

Significant concurrent positions outside the Company:
Representative Director and President, CMIC Bio Co., Ltd.
[Reasons for nomination as candidate for Corporate Director]
Mr. Takeshi Hamaura possesses extensive achievements and highly specialized knowledgeof formulation technology development and in the CMC area. As the Company expects him
to continue to perform a decision-making and supervisory role in management based on his
business experience and achievements, it again nominated him as a candidate for Corporate
Director.

9

Candidate No.

7

New election
Number of the Company’s shares owned: – shares
Attendance to meetings of the Board of Directors: –[Career summary, and position and responsibility in the Company]
Apr. 1975 Joined Toray Industries, Inc.
Apr. 1981(Seconded to) Economic Planning Agency (currently Cabinet Office)Aug. 1990 Treasurer, Toray Industries (America), Inc.
June 2003

General Manager, Finance Dept.; General Manager on Special Assignment,
Corporate Strategic Planning Division, Toray Industries, Inc.

June 2005

Member of the Board, General Manager, Corporate Strategic Planning
Division, Toray Industries, Inc.

Yoshiyuki Inamoto

June 2007

Director, in charge of Corporate Strategic Planning, Toray Industries, Inc.

(June 12, 1952)

June 2011

Senior Director, Toray Industries, Inc.

Nov. 2021 Joined the Company, Vice President (to present)[Reasons for nomination as candidate for Corporate Director]
Mr. Yoshiyuki Inamoto possesses extensive experience and management experience infinance, corporate planning and business development at a major chemical company. As theCompany expects him to perform a decision-making and supervisory role in management
based on his business experience and achievements, it has newly nominated him as a
candidate for Corporate Director.

10Candidate No.

8

Reelection External
Number of the Company’s shares owned: – shares
Attendance to meetings of the Board of Directors: 12/12 (100%)[Career summary, and position and responsibility in the Company]
Dec. 1973 Joined Department of Surgery II, The University of Tokyo Hospital
Apr. 1983

Joined Department of Surgery II, Faculty of Medicine, University of Yamanashi

Apr. 1993

Joined Hoechst Japan Co., Ltd. (currently Sanofi K.K.)

Jan. 2005

Joined GlaxoSmithKline K.K.

Sept. 2011 Specially Appointed Professor, Department of Clinical Research, Faculty of
Medicine, University of Yamanashi
Sept. 2014 Specially Appointed Professor, Department of Advanced Biomedical Research,
Faculty of Medicine, University of Yamanashi (to present)
Apr. 2015

Vice President, University of Yamanashi (to present)

Dec. 2016 External Corporate Director, the Company (to present)

Masaru Iwasaki(May 3, 1947)

Significant concurrent positions outside the Company:
Vice President, University of Yamanashi
Program Director, Japan Agency for Medical Research and Development
Visiting Professor, Juntendo University School of Medicine[Reasons for nomination as candidate for External Corporate Director and summaryof his expected role]
After working as a clinician in the oncology area, Mr. Masaru Iwasaki possesses experienceand achievements from serving in important positions for large pharmaceutical corporations
in areas including product strategy planning and product development. He has performed an
important role in the Company’s management as an External Corporate Director from atechnical perspective of pharmaceuticals and healthcare since December 2016. As theCompany expects him to continue fulfilling the role of advising and supervising its overallmanagement, it again nominated him as a candidate for External Corporate Director.

11

Candidate No.

9

Reelection External Independent
Number of the Company’s shares owned: – shares
Attendance to meetings of the Board of Directors: 12/12 (100%)[Career summary, and position and responsibility in the Company]
Apr. 1980 Joined Ministry of Health and Welfare (currently Ministry of Health, Labourand Welfare)
July 2000

Director, Public Relations Office, General Coordination Division, Minister’s
Secretariat, Ministry of Health and Welfare

July 2004

Director, National Health Insurance Division and Director, General Affairs
Division, Health Insurance Bureau, Ministry of Health, Labour and Welfare

July 2009

Deputy Director-General (in charge of Medical Insurance, Health Policy, HealthCare and Long-term Care Integration), Ministry of Health, Labour and Welfare

Sept. 2012 Director-General for Policy Planning and Evaluation (in charge of Social
Security), Ministry of Health, Labour and Welfare
July 2014

Director General, Health Insurance Bureau, Ministry of Health, Labour andWelfareJune 2016 Director-General for Regional Revitalization, Headquarters for Overcoming
Population Decline and Vitalizing Local Economy in Japan, Cabinet Secretariat

Takeshi Karasawa(August 29, 1956)

Aug. 2016 Retired from Cabinet Secretariat
Dec. 2018 External Corporate Director, the Company (to present)
Significant concurrent positions outside the Company:
Project Professor, Graduate School of Media and Governance, Keio University
Outside Director, Value HR Co., Ltd.
[Reasons for nomination as candidate for External Corporate Director and summaryof his expected role]
Mr. Takeshi Karasawa possesses extensive achievements and highly specialized knowledgeof healthcare and nursing care related policies and the social security system in generalfrom his experience in government administration. He has performed an important role in
the Company’s management as an External Corporate Director from an independent
perspective since December 2018. In addition, as a Nomination and Remuneration
Committee member, he proactively expresses his opinions and contributes to thedeliberations of the Committee. As the Company expects him to continue providing us withpractical advice on the Company’s business strategy and promotion, it again nominated him
as a candidate for External Corporate Director.

12

Candidate No.

10

Reelection External Independent
Number of the Company’s shares owned: – shares
Attendance to meetings of the Board of Directors: 11/12 (92%)[Career summary, and position and responsibility in the Company]
Oct. 1981 Joined Nomura Research Institute, Ltd.
Sept. 1985 Management Consultant, McKinsey & Company

Eriko Kawai

Oct. 1986

Fund Manager, Mercury Asset Management plc, SG Warburg

Nov. 1995

Chief Investment Officer, Yamaichi Regent ABC Polska

July 1998

Joined Bank for International Settlements

Oct. 2004

Senior Pension Fund Administrator, Organisation for Economic Co-operation
and Development (OECD)

Mar. 2008

Representative, Kawai Global Intelligence

Apr. 2012

Professor, Institute for the Promotion of Excellence in Higher Education,
Kyoto University

Apr. 2013

Professor, Institute for Liberal Arts and Sciences, Kyoto University

Apr. 2014

Professor, Graduate School of Advanced Integrated Studies in Human
Survivability, Kyoto University

Dec. 2017

External Audit and Supervisory Board Member, the Company

Dec. 2019

External Corporate Director, the Company (to present)

Apr. 2021

Professor, Emeritus, Kyoto University (to present)(April 28, 1958)
Significant concurrent positions outside the Company:
Specially Appointed Professor, Social Innovation Center, Graduate School of Advanced
Integrated Studies in Human Survivability, Kyoto University
Outside Director, Daiwa Securities Group Inc.
Outside Director, Mitsui Fudosan Co., Ltd.
Outside Audit & Supervisory Board Member, Yamaha Motor Co., Ltd.
[Reasons for nomination as candidate for External Corporate Director and summaryof her expected role]
In addition to her extensive experience in international corporations, Ms. Eriko Kawai
possesses experience and achievements as a corporate manager and outstanding knowledge
in management. She has performed an important role in the Company’s management as anExternal Corporate Director from an independent perspective since December 2019. In
addition, as a Nomination and Remuneration Committee member, she proactively expresses
her opinions and contributes to the deliberations of the Committee. As the Company
expects her to continue providing us with practical advice on the Company’s businessstrategy and promotion using her experience and knowledge, it again nominated her as a
candidate for External Corporate Director.

13

Candidate No.

11

New election External Independent
Number of the Company’s shares owned: – shares
Attendance to meetings of the Board of Directors: –[Career summary, and position and responsibility in the Company]
June 1981 Co-Founder and Partner, BERKELEY ANTIBODY COMPANY, INC.
Apr. 1983

President and Director, BERKELEY ANTIBODY COMPANY, INC.

Jan. 1986

Joined VIVIGEN, INC.

Jan. 1988

President, VIVIGEN, INC.

Mar. 1993

Joined MCKINSEY & COMPANY

June 1994

Director, UNM RAINFOREST INNOVATIONS (to present)

Feb. 1995

President & CEO, GREGG L. MAYER & COMPANY, INC. (to present)

Sept. 1996 Director, KAISER PERMANENTE INTERNATIONAL

Gregg Lindstrom
Mayer(August 15, 1958)

Significant concurrent positions outside the Company:
Director, DISEASE MANAGEMENT ASSOCIATION OF JAPAN
Co-Chair, Population Health Research Committee ASIA PACIFIC SOCIETY FORHEALTH SUPPORT SCIENCES[Reasons for nomination as candidate for External Corporate Director and summaryof his expected role]
Mr. Gregg Lindstrom Mayer possesses extensive experience and expertise in disease
management, business development, etc. in the pharmaceutical, medical device,biotechnology and healthcare industries. He is also familiar with Japan’s healthcare
administration and the Company expects that he will be able to provide us with practicaladvice on the Company’s global strategy and promotion. The Company therefore newly
nominated him as a candidate for External Corporate Director.

Notes:

1. Special interest between the candidates and the Company:(1) The Company makes donations to University of Yamanashi in which Mr. Masaru Iwasaki serves as Vice
President.
(2) There is no special interest between the other candidates and the Company.
2. Mr. Masaru Iwasaki, Mr. Takeshi Karasawa, Ms. Eriko Kawai and Mr. Gregg Lindstrom Mayer are candidates forExternal Corporate Director.
3. Mr. Masaru Iwasaki is currently an External Corporate Director of the Company, and at the conclusion of thismeeting, his tenure as External Corporate Director will have been five (5) years.
4. Mr. Takeshi Karasawa is currently an External Corporate Director of the Company, and at the conclusion of thismeeting, his tenure as External Corporate Director will have been three (3) years.
5. Ms. Eriko Kawai is currently an External Corporate Director of the Company, and at the conclusion of this meeting,her tenure as External Corporate Director will have been two (2) years. While the Company also makes donations
to the Kyoto University Graduate School, where she is a professor, according to the standards established by theCompany, we judge that this does not affect her independence.
6. The Company has entered into an agreement with Mr. Masaru Iwasaki, Mr. Takeshi Karasawa and Ms. Eriko
Kawai to limit their liability amount to the minimum liability amount as provided for by Article 425, paragraph(1) of the Companies Act. If their reelection is approved, the Company plans to continue said limited liability
agreement with each one of them. If the election of Mr. Gregg Lindstrom Mayer is approved, the Company plansto enter into the same limited liability agreement with him.
7. The Company has submitted notification to the Tokyo Stock Exchange that Mr. Takeshi Karasawa and Ms. Eriko
Kawai have been appointed as independent officers as provided for by the aforementioned exchange. Should theirreelection be approved, the Company intends to submit notification that they have been appointed as independent
officers. If the election of Mr. Gregg Lindstrom Mayer is approved, the Company plans to submit notification to
the aforementioned exchange concerning his appointment as an independent officer.
8. The Company has entered into a directors and officers liability insurance policy as provided for in Article 430-3,
paragraph (1) of the Companies Act with an insurance company. In the event that an insured is claimed for damagesby a shareholder or a third party in connection with the performance of their duties, the policy will cover losses
including indemnification for such damages and litigation expenses. If this proposal is approved and adopted, andeach of them is appointed as a Corporate Director of the Company, they will be included as insureds of theinsurance policy. In addition, the Company plans to renew the policy with the same details at the next renewal.

14

<<Reference>> Skill Matrix of Candidates for Corporate Director and Audit and Supervisory Board
Members
Name

Finance/
Accounting

Legal affairs/
Riskmanagement

Businessknowledge●●

Globalbusiness

Corporate Directors

Kazuo Nakamura●

Keiko Oishi

●

●

●

Makoto Matsukawa

●

●

●

Wataru Mochizuki●

Toru Fujieda

●

●

●

Takeshi Hamaura

●

●

●

Yoshiyuki Inamoto

●

●

●

●

Masaru Iwasaki

Audit andSupervisory
Board
Members
Note:

Corporate
management

●
●

●
●

Takeshi Karasawa●●

Eriko Kawai●●

Gregg Lindstrom Mayer●●●

Yasuo Yoshimune●

Kei Hata●

Hidetoshi Watanabe●●

Masaru Ota

●

●

●

●

●

The above list indicates up to three items that are particularly expected of each candidate, and does not exhaustively
describe all the knowledge and experience possessed by each candidate.

15